SCHEMBL23701378

SCHEMBL23701378

COc1ccc(N2CC3CN(C(=O)NCCO)CC3C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GFER P55789 2/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GRIN2B Q13224 4/20 0.43
LMNA P02545 2/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA7 P36544 1/20 0.43
CHRNA4 P43681 1/20 0.43
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
NAMPT P43490 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701377 1.00 POLB (0.46) POLBL3MBTL1GFERNPC1MAPT
SCHEMBL27400151 0.90 POLB (0.48) POLBL3MBTL1GFERNPC1MAPT
SCHEMBL23701429 0.88 ACACB (0.46)
SCHEMBL23701430 0.88 ACACB (0.46)
SCHEMBL23701418 0.87 CHRNB2 (0.48) POLBL3MBTL1GFERNPC1MAPT
SCHEMBL23701416 0.87 CHRNB2 (0.48) POLBL3MBTL1GFERNPC1MAPT
SCHEMBL27400039 0.86 TP53 (0.41) L3MBTL1MAPTSMN1; SMN2GRIN2BLMNA
SCHEMBL23701440 0.80 GAA (0.47) POLBNPC1MAPTSMN1; SMN2LMNA
SCHEMBL23701441 0.80 GAA (0.47) POLBNPC1MAPTSMN1; SMN2LMNA
SCHEMBL23701415 0.79 DRD2 (0.37) POLBKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 POLB 2518/4885L3MBTL1 835/4885GFER 783/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 POLB 2518/4885L3MBTL1 835/4885GFER 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.